Celltrion wins UNDP tender to supply anticancer treatments to Turkmenistan
Celltrion Healthcare, South Korean biosimilar giant Celltrion’s sales unit, announced Wednesday that the company has won the United Nations Development Program’s tender to supply anticancer drugs to Turkmenistan.
The UNDP is a UN agency dedicated to eradicating poverty and reducing inequalities through the sustainable development of nations in more than 170 countries and territories.
Celltrion Healthcare said the company joined the tender that opened in May this year, and that the result was announced last month.
According to Celltrion Healthcare, the company will supply its blood cancer biosimilar Truxima, and its metastatic colorectal and breast cancer treatment Vegzelma to Turkmenistan.
The company added that the supply of anticancer biosimilars is expected to begin by the end of this year.
The value of the tender, as well as the quantity of its anticancer treatments supply, have not been disclosed by the company.
“It is meaningful for us to supply our treatments to help patients in the country,” an official from Celltrion Healthcare said. “We believe that Truxima and Vegzelma will become the most effective, and economically viable treatment options, not only in developed countries but also in developing countries."
Celltrion Healthcare said that the company will participate more in international organizations’ tenders in the future.
Both Truxima and Vegzelma are widely prescribed anticancer treatments developed by Celltrion.
According to the world’s largest contract research organization IQVIA’s data, Truxima, the first biosimilar of Roche’s blockbuster cancer drug Rituxan, has secured 22 percent market share in the European market as of the second quarter this year. In the US, its market share stood at 30 percent in the third quarter, according to separate data from Symphony Health.
Vegzelma, an anti-cancer monoclonal antibody treatment biosimilar to Avastin, is increasing its presence in European countries after its launch in October 2022, Celltrion Healthcare said. The drug's market shares in Finland and Germany stood at 45 percent and 21 percent, respectively.
(责任编辑:쇼핑)
- Four days of jazz festivities take over Jara Island
- Seoul proposes safety measures to prevent poor construction
- Seoul proposes safety measures to prevent poor construction
- [Korean History] In 2004, serial murderer with goal to kill 100 was stopped at 20
- Kakao Bank to acquire 10% stake in Indonesian digital bank
- [Hello Hangeul] Americans seeking to visit Korea learn the language in LA
- [Korea Beyond Korea] Anthropologist stresses multidisciplinary approach for strong Korean studies
- 'Justice will prevail': G
- [Herald Review] Ive gives a sneak peek of new album, kicks off first world tour with Seoul gigs
- [Korean History] In 2004, serial murderer with goal to kill 100 was stopped at 20
- [From the scene] Jazz music livens up Seoul's streets
- Marking 105th anniversary of independence, Poland highlights growing ties with Gyeonggi Province
- 'We overcame together': NCT127 returns on more solid ground
- Cold wave hit S. Korea amid forecast of even chillier morning
- Kakao Bank to acquire 10% stake in Indonesian digital bank
- Kyobo Life chairman wins top industry honor
- Seoul shares slide 2.3% after record gains over short selling ban
- Samsung C&T gears for 2023 Smart City Expo World Congress
- [Korean History] 2002, when Korea soared through World Cup
- LX International to acquire 60% stake in Indonesian nickel mine
- [Korea Beyond Korea] In Paris, soaring demand for Korean studies yet to be fully met views+
- Over 1,300 rescue workers still traumatized by Itaewon Halloween tragedy views+
- Hyundai Motor shows off air mobility, drone tech at Seoul defense fair views+
- Jeonse scams cause W510b in losses, with less than 25% recovered: lawmaker views+
- Hyundai Rotem to showcase new ground weapons systems at Seoul expo views+
- Yoon, doctors set to clash over medical school quota views+
- S. Korea, US, Japan install trilateral communication hotline amid N. Korea, China challenges views+
- GOT7’s Youngjae to release 1st solo LP “Do It” next month views+
- Yoon lauds rapid growth of Korean defense industry views+
- 윤 대통령 “국민소통·현장소통·당정소통 강화하라” views+